糠酸莫米松治疗常年变应性鼻炎患儿的临床疗效及对其症状积分的影响研究

Study on the Clinical Efficacy of Mometasone Furoate in the Treatment of Children with Perennial Allergic Rhinitis and Its Effect on Symptom Scores

目的探讨糠酸莫米松治疗常年变应性鼻炎(PAR)患儿的临床疗效及对其症状积分的影响.方法选取2019年3月—2020年3月该院收治的92例PAR患儿为研究对象,采用随机数字表法将所有患儿分为对照组与观察组,每组46例.对照组患儿采用口服氯雷他定治疗,观察组患儿采用鼻内吸入糠酸莫米松治疗.比较两组患儿治疗前后鼻炎症状积分、生活质量以及不良反应.结果两组治疗前的各项鼻炎症状积分及总分相比,组间差异无统计学意义(P>0.05);治疗后,两组各项鼻炎症状积分及总分均显著低于同组治疗前,且观察组各项鼻炎症状积分及总分均低于对照组,组间差异有统计学意义(P<0.05).两组治疗前的鼻结膜炎生活质量调查问卷(RQLQ)各方面评分相比,组间差异无统计学意义(P>0.05);治疗后,两组RQLQ各方面评分均较同组治疗前降低,且观察组RQLQ各方面评分均低于对照组,组间差异有统计学意义(P<0.05).两组患儿均未出现药物不良反应.结论临床针对PAR患儿采用糠酸莫米松治疗,能有效改善患儿的临床症状,提高其生活质量,且无不良反应.

Objective To investigate the clinical efficacy of mometasone furoate in the treatment of children with perennial allergic rhinitis(PAR)and its influence on symptom scores.Methods A total of 92 children with PAR who were treated in the hospital from March 2019 to March 2020 were selected as the research objects,and all the children were divided into a control group and an observation group by random number table method,with 46 cases in each group.The children in the control group were treated with oral loratadine,and the children in the observation group were treated with intranasal inhalation of mometasone furoate.The rhinitis symptom scores,quality of life before and after treatment and adverse reactions were compared between the two groups.Results There was no significant difference in the scores of various rhinitis symptoms and total scores between the two groups before treatment(P>0.05);after treatment,the scores of various rhinitis symptoms and total scores in the two groups were significantly lower than those before treatment in the same group,and the scores of various rhinitis symptoms and total scores in the observation group were lower than those in the control group,and the differences between the groups were statistically significant(P<0.05).There was no significant difference in the scores of rhinoconjunctivitis quality of life questionnaire(RQLQ)between the two groups before treatment(P>0.05);after treatment,the scores of all aspects of RQLQ in the two groups were lower than those in the same group before treatment,and the scores of all aspects of RQLQ in the observation group were lower than those in the control group,and the differences between the groups were statistically significant(P<0.05).There were no adverse drug reactions in both groups.Conclusion The clinical use of mometasone furoate for the treatment of children with PAR can effectively improve the clinical symptoms of children and improve their quality of life without adverse reactions.